RS58423B1 - Upotreba tiazolo pirimidinona za lečenje inflamatorne bolesti creva - Google Patents

Upotreba tiazolo pirimidinona za lečenje inflamatorne bolesti creva

Info

Publication number
RS58423B1
RS58423B1 RS20190216A RSP20190216A RS58423B1 RS 58423 B1 RS58423 B1 RS 58423B1 RS 20190216 A RS20190216 A RS 20190216A RS P20190216 A RSP20190216 A RS P20190216A RS 58423 B1 RS58423 B1 RS 58423B1
Authority
RS
Serbia
Prior art keywords
compound
treatment
dose
pharmaceutical preparation
preparation
Prior art date
Application number
RS20190216A
Other languages
English (en)
Serbian (sr)
Inventor
Chaitanya Dutt
Vijay Chauthaiwale
Ram Gupta
Shitalkumar Zambad
Shailesh Deshpande
Jignesh Kotecha
Ramesh Gupta
Sanjay Srivastava
Laxmikant Chhipa
Jaya Abraham
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of RS58423B1 publication Critical patent/RS58423B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
RS20190216A 2013-05-14 2014-05-12 Upotreba tiazolo pirimidinona za lečenje inflamatorne bolesti creva RS58423B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1718MU2013 2013-05-14
IN2309MU2013 2013-07-09
EP14728622.3A EP2996693B1 (en) 2013-05-14 2014-05-12 Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
PCT/IB2014/000707 WO2014184631A1 (en) 2013-05-14 2014-05-12 Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
RS58423B1 true RS58423B1 (sr) 2019-04-30

Family

ID=50896342

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190216A RS58423B1 (sr) 2013-05-14 2014-05-12 Upotreba tiazolo pirimidinona za lečenje inflamatorne bolesti creva

Country Status (28)

Country Link
US (2) US9610247B2 (OSRAM)
EP (1) EP2996693B1 (OSRAM)
JP (1) JP6407974B2 (OSRAM)
KR (1) KR102239649B1 (OSRAM)
CN (1) CN105209043B (OSRAM)
AU (1) AU2014266968B2 (OSRAM)
BR (1) BR112015028581B1 (OSRAM)
CA (1) CA2912011C (OSRAM)
CY (1) CY1121280T1 (OSRAM)
DK (1) DK2996693T3 (OSRAM)
EA (1) EA030590B1 (OSRAM)
ES (1) ES2712705T3 (OSRAM)
HR (1) HRP20190315T1 (OSRAM)
HU (1) HUE042691T2 (OSRAM)
IL (1) IL242490B (OSRAM)
LT (1) LT2996693T (OSRAM)
MX (1) MX358198B (OSRAM)
MY (1) MY179215A (OSRAM)
PH (1) PH12015502560B1 (OSRAM)
PL (1) PL2996693T3 (OSRAM)
PT (1) PT2996693T (OSRAM)
RS (1) RS58423B1 (OSRAM)
SG (1) SG11201509275PA (OSRAM)
SI (1) SI2996693T1 (OSRAM)
SM (1) SMT201900111T1 (OSRAM)
TW (1) TWI661828B (OSRAM)
UA (1) UA117244C2 (OSRAM)
WO (1) WO2014184631A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781922B (zh) * 2016-03-14 2022-11-01 日商參天製藥股份有限公司 由葡甲胺或其鹽構成之防腐劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002533A1 (en) * 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
TWI500623B (zh) * 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
US8541430B2 (en) * 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones

Also Published As

Publication number Publication date
CN105209043B (zh) 2019-07-02
HRP20190315T1 (hr) 2019-04-05
PL2996693T3 (pl) 2019-05-31
CA2912011A1 (en) 2014-11-20
SG11201509275PA (en) 2015-12-30
AU2014266968A1 (en) 2015-12-03
US20160120801A1 (en) 2016-05-05
SI2996693T1 (sl) 2019-04-30
ES2712705T3 (es) 2019-05-14
PH12015502560A1 (en) 2016-02-22
EP2996693B1 (en) 2018-12-12
IL242490B (en) 2018-11-29
US20170157129A1 (en) 2017-06-08
EA030590B1 (ru) 2018-08-31
AU2014266968B2 (en) 2019-09-19
EA201592159A1 (ru) 2016-04-29
US10471005B2 (en) 2019-11-12
CN105209043A (zh) 2015-12-30
US9610247B2 (en) 2017-04-04
UA117244C2 (uk) 2018-07-10
TW201513866A (zh) 2015-04-16
BR112015028581B1 (pt) 2022-05-03
KR102239649B1 (ko) 2021-04-12
KR20160008571A (ko) 2016-01-22
SMT201900111T1 (it) 2019-02-28
TWI661828B (zh) 2019-06-11
MY179215A (en) 2020-11-02
BR112015028581A2 (pt) 2017-07-25
MX2015015682A (es) 2016-07-20
PH12015502560B1 (en) 2016-02-22
PT2996693T (pt) 2019-02-27
HUE042691T2 (hu) 2019-07-29
DK2996693T3 (en) 2019-03-18
NZ714098A (en) 2020-12-18
JP6407974B2 (ja) 2018-10-17
LT2996693T (lt) 2019-03-12
CY1121280T1 (el) 2020-05-29
EP2996693A1 (en) 2016-03-23
WO2014184631A1 (en) 2014-11-20
MX358198B (es) 2018-08-08
CA2912011C (en) 2021-10-26
JP2016518440A (ja) 2016-06-23

Similar Documents

Publication Publication Date Title
US20200000726A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
JP6796132B2 (ja) 液体剤形中の薬学的活性化合物放出性多層微小粒子
WO2009047801A1 (en) Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
JP6566638B2 (ja) メサラミンの放出制御固形製剤
KR102381586B1 (ko) 메살라진의 경구용 약제학적 조성물
JP2014501267A (ja) メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法
KR20210152588A (ko) 리나클로타이드의 지연 방출 조성물
JP2022093472A (ja) リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法
US10471005B2 (en) Low dose pharmaceutical composition
NZ714098B2 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease